MagForce partners with Mayo Clinic
BERLIN—MagForce AG and Mayo Clinic have announced a preclinical research agreement centered on MagForce's NanoTherm therapy. Per the agreement, Mayo Clinic will launch and fund a research program applying NanoTherm to investigate the preclinical efficiency of the therapy in pancreatic and liver cancers. Dev Mukhopadhyay, professor of biochemistry/molecular biology, will direct the project, which aims to achieve preclinical proof of concept in order to file the clinical development program supporting U.S. Food and Drug Administration premarket approval of NanoTherm in these indications.
"A positive outcome of this new project would be the first important milestone to set up a clinical development program in gastrointestinal cancer in cooperation with medical key opinion leaders throughout the United States," said Dr. Hoda Tawfik, vice president of R&D/Medical Affairs at MagForce.